Latest & greatest articles for pregnancy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pregnancy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pregnancy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pregnancy

61. Dolutegravir (Tivicay, Triumeq, Juluca): signal of increased risk of neural tube defects; do not prescribe to women seeking to become pregnant; exclude pregnancy before initiation and advise use of effective contraception

Dolutegravir (Tivicay, Triumeq, Juluca): signal of increased risk of neural tube defects; do not prescribe to women seeking to become pregnant; exclude pregnancy before initiation and advise use of effective contraception Dolutegravir (Tivicay▼, Triumeq▼, Juluca▼): signal of increased risk of neural tube defects; do not prescribe to women seeking to become pregnant; exclude pregnancy before initiation and advise use of effective contraception - GOV.UK GOV.UK uses cookies to make the site (...) simpler. Search Dolutegravir (Tivicay▼, Triumeq▼, Juluca▼): signal of increased risk of neural tube defects; do not prescribe to women seeking to become pregnant; exclude pregnancy before initiation and advise use of effective contraception New safety recommendations have been issued while an EU review evaluates cases of neural tube defects in babies born to mothers who became pregnant while taking the HIV medicine dolutegravir. Published 22 June 2018 From: Therapeutic area: , , Contents Advice

MHRA Drug Safety Update2018

62. Updated measures for pregnancy prevention during retinoid use

Updated measures for pregnancy prevention during retinoid use European Medicines Agency - News and Events - Updated measures for pregnancy prevention during retinoid use Search for medicines Main navigation News and press releases Updated measures for pregnancy prevention during retinoid use Press release 23/03/2018 Updated measures for pregnancy prevention during retinoid use Warning on possible risk of neuropsychiatric disorders also to be included for oral retinoids The European Medicines (...) Agency (EMA) has completed its review of retinoid medicines, and confirmed that an update of measures for pregnancy prevention is needed. In addition, a warning on the possibility that neuropsychiatric disorders (such as depression, anxiety and mood changes) may occur will be included in the prescribing information for oral retinoids (those taken by mouth). Retinoids include the active substances acitretin, adapalene, alitretinoin, bexarotene, isotretinoin, tazarotene and tretinoin. They are taken

European Medicines Agency - EPARs2018

63. New measures to avoid valproate exposure in pregnancy endorsed

New measures to avoid valproate exposure in pregnancy endorsed European Medicines Agency - News and Events - New measures to avoid valproate exposure in pregnancy endorsed Search for medicines Main navigation News and press releases New measures to avoid valproate exposure in pregnancy endorsed Press release 23/03/2018 New measures to avoid valproate exposure in pregnancy endorsed Member State representatives agree new restrictions and pregnancy prevention programme The CMDh 1 has endorsed new (...) measures to avoid exposure of babies to valproate medicines in the womb, because exposed babies are at high risk of malformations and developmental problems. Valproate-containing medicines have been approved nationally in the EU to treat epilepsy and bipolar disorder and in some countries for prevention of migraine. The new measures include a ban on the use of such medicines for migraine or bipolar disorder during pregnancy, and a ban on treating epilepsy during pregnancy unless there is no other

European Medicines Agency - EPARs2018

67. Metformin exposure in first trimester of pregnancy and risk of all or specific congenital anomalies: exploratory case-control study.

Metformin exposure in first trimester of pregnancy and risk of all or specific congenital anomalies: exploratory case-control study. OBJECTIVE: To investigate whether exposure to metformin during the first trimester of pregnancy, for diabetes or other indications, increases the risk of all or specific congenital anomalies. DESIGN: Population based exploratory case-control study using malformed controls. Cases of 29 specific subgroups of non-genetic anomalies, and all non-genetic anomalies (...) combined, were compared with controls (all other non-genetic anomalies or genetic syndromes). SETTING: 11 EUROmediCAT European congenital anomaly registries surveying 1 892 482 births in Europe between 2006 and 2013. PARTICIPANTS: 50 167 babies affected by congenital anomaly (41 242 non-genetic and 8925 genetic) including live births, fetal deaths from 20 weeks' gestation, and terminations of pregnancy for fetal anomaly. MAIN OUTCOME MEASURE: Odds ratios adjusted for maternal age, registry, multiple

BMJ2018

68. Vitamin D and risk of pregnancy related hypertensive disorders: mendelian randomisation study.

Vitamin D and risk of pregnancy related hypertensive disorders: mendelian randomisation study. OBJECTIVE: To use mendelian randomisation to investigate whether 25-hydroxyvitamin D concentration has a causal effect on gestational hypertension or pre-eclampsia. DESIGN: One and two sample mendelian randomisation analyses. SETTING: Two European pregnancy cohorts (Avon Longitudinal Study of Parents and Children, and Generation R Study), and two case-control studies (subgroup nested within (...) variables. MAIN OUTCOME MEASURES: Gestational hypertension and pre-eclampsia defined according to the International Society for the Study of Hypertension in Pregnancy. RESULTS: In the conventional multivariable analysis, the relative risk for pre-eclampsia was 1.03 (95% confidence interval 1.00 to 1.07) per 10% decrease in 25-hydroxyvitamin D level, and 2.04 (1.02 to 4.07) for 25-hydroxyvitamin D levels <25 nmol/L compared with ≥75 nmol/L. No association was found for gestational hypertension. The

BMJ2018

69. Mifepristone Pretreatment for the Medical Management of Early Pregnancy Loss.

Mifepristone Pretreatment for the Medical Management of Early Pregnancy Loss. BACKGROUND: Medical management of early pregnancy loss is an alternative to uterine aspiration, but standard medical treatment with misoprostol commonly results in treatment failure. We compared the efficacy and safety of pretreatment with mifepristone followed by treatment with misoprostol with the efficacy and safety of misoprostol use alone for the management of early pregnancy loss. METHODS: We randomly assigned (...) % of the women in the misoprostol-alone group (P=0.31); pelvic infection was diagnosed in 1.3% of the women in each group. CONCLUSIONS: Pretreatment with mifepristone followed by treatment with misoprostol resulted in a higher likelihood of successful management of first-trimester pregnancy loss than treatment with misoprostol alone. (Funded by the National Institute of Child Health and Human Development; PreFaiR ClinicalTrials.gov number, NCT02012491 .).

NEJM2018

71. Valproate medicines (Epilim, Depakote): Pregnancy Prevention Programme materials online

Valproate medicines (Epilim, Depakote): Pregnancy Prevention Programme materials online Valproate medicines (Epilim▼, Depakote▼): Pregnancy Prevention Programme materials online - GOV.UK GOV.UK uses cookies to make the site simpler. Search Valproate medicines (Epilim▼, Depakote▼): Pregnancy Prevention Programme materials online Use materials online now and hardcopies arriving over the coming weeks by post to ensure women and girls of childbearing potential on valproate medicines meet (...) the requirements of the Pregnancy Prevention Programme. Published 24 May 2018 From: Therapeutic area: , , , Contents Act now to use the following to support the new Valproate Pregnancy Prevention Programme: – to be given by pharmacists to all female patients who are dispensed valproate medicines to inform them of the risks – to be provided to girls (of any age) and women of childbearing potential (or their parent/caregiver/responsible person) taking any medicine containing valproate – for all prescribers

MHRA Drug Safety Update2018

74. Pregnancy Exercise and Nutrition With Smartphone Application Support: A Randomized Controlled Trial

Pregnancy Exercise and Nutrition With Smartphone Application Support: A Randomized Controlled Trial 29630009 2018 04 23 1873-233X 131 5 2018 May Obstetrics and gynecology Obstet Gynecol Pregnancy Exercise and Nutrition With Smartphone Application Support: A Randomized Controlled Trial. 818-826 10.1097/AOG.0000000000002582 To evaluate the effect of a healthy lifestyle package (an antenatal behavior change intervention supported by smartphone application technology) on the incidence (...) of gestational diabetes mellitus (GDM) in overweight and obese women. Women with body mass indexes (BMIs) 25-39.9 were enrolled into this randomized controlled trial. The intervention consisted of specific dietary and exercise advice that addressed behavior change supported by a tailor-designed smartphone application. Women in the control group received usual care. The primary outcome was the incidence of GDM at 28-30 weeks of gestation. To reduce GDM from 15% to 7.2%, we estimated that 506 women would

EvidenceUpdates2018

75. Continuous glucose monitoring during diabetic pregnancy (GlucoMOMS): A multicentre randomized controlled trial

Continuous glucose monitoring during diabetic pregnancy (GlucoMOMS): A multicentre randomized controlled trial 29603547 2018 05 08 1463-1326 2018 Mar 30 Diabetes, obesity & metabolism Diabetes Obes Metab Continuous glucose monitoring during diabetic pregnancy (GlucoMOMS): A multicentre randomized controlled trial. 10.1111/dom.13310 Diabetes is associated with a high risk of adverse pregnancy outcomes. Optimal glycaemic control is fundamental and is traditionally monitored with self-measured (...) glucose profiles and periodic HbA1c measurements. We investigated the effectiveness of additional use of retrospective continuous glucose monitoring (CGM) in diabetic pregnancies. We performed a nationwide multicentre, open label, randomized, controlled trial to study pregnant women with type 1 or type 2 diabetes who were undergoing insulin therapy at gestational age < 16 weeks, or women who were undergoing insulin treatment for gestational diabetes at gestational age < 30 weeks. Women were randomly

EvidenceUpdates2018

79. Largest study to date shows overall use of antipsychotics in pregnancy does not appear to significantly increase the risk of congenital malformations

Largest study to date shows overall use of antipsychotics in pregnancy does not appear to significantly increase the risk of congenital malformations Largest study to date shows overall use of antipsychotics in pregnancy does not appear to significantly increase the risk of congenital malformations | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Largest study to date shows overall use of antipsychotics in pregnancy does not appear to significantly increase the risk of congenital malformations Article Text Causes and risk factors Largest study

Evidence-Based Mental Health2018